Brief: Ligand Pharmaceuticals Q4 EPS USD 1.03
27/02/2024 12:00
Feb 27 (Reuters) - Ligand Pharmaceuticals Q4 basic EPS USD 1.04. * Q4 operating income USD -3.358 million * Q4 net income continuing operations USD 18.188 million * Q4 pretax profit USD 17.097 million * outlook FY revenue USD 25-27 million
Recent news on Ligand Pharmaceuticals Incorporated
See all newsBrief: Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary
Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Brief: Ligand Pharmaceuticals Q2 EPS USD 2.22
U.S. RESEARCH ROUNDUP-Equinix, Goldman Sachs, JPMorgan